Charles River Laboratories International, Inc.: stock overview

CRLNYSEHealthcare · Services-Commercial Physical & Biological Research

Price

$337.97

November 13, 2026Market cap $16.6B

DCF calculator

What Ploutos Investor adds for Charles River Laboratories International

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.

In short

Charles River Laboratories International had revenue of $4.0B over the last 12 months and net income of $40M, a net margin of 1.0%. Revenue grew by 6.6% a year on average over the last 5 years. It has net debt of $2.2B. It pays no dividend.

From its SEC filings (latest fiscal year to December 27, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$16.6B
49.23M shares
P/E
–
median of 3 years: 25.6
Revenue, 12 months
$4.0B
+6.6% a year over 5 years
Net margin
1.0%
FY2025: -3.6%, above 20% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2023–FY2025 fiscal years

-1.4% a year over 2 years

  • FY2025Dec 27, 202510-K
    Revenue$4.0B
  • FY2024Dec 28, 202410-K
    Revenue$4.0B
  • FY2023Dec 30, 202310-K
    Revenue$4.1B

Fiscal years in figures

CRL's revenue, profit, cash flow and dividend with each year-end price, from FY2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $10.0B
$16.6B
Enterprise value 
$18.9B
P/E 
–
EV / EBIT 
118.8
EV / Revenue 
4.8
P/B 3-year median: 3.2
5.2
FCF yield 3-year median: 5.2%
2.4%
Earnings yield 3-year median: 0.1%
–

Profitability

Operating margin 
4.0%
Net margin 3-year median: 0.5%
1.0%
ROIC 
2.3%
ROIC, 5-year average 
5.9%
ROE 
1.3%

Growth

Revenue, yearly change 
-0.9%
EPS, yearly change 
–
FCF, yearly change 
+3.4%
Revenue, average a year 
+6.6%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$200M
Total debt 
$2.9B
Of which operating leases 
$405M
Net debt 
$2.2B
Net debt / EBITDA 
4.0x
Interest cover 
1.5x
Current ratio 
1.41

Balance sheet of September 26, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
2.17%
Total returned 
2.17%
Shares, yearly change 
-3.7%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 87).

Operating margin

0.6%

Above 24% of the 43 companies in its industry, and 36% of all.

Net margin

-3.6%

Above 20% of the 42 companies in its industry, and 26% of all.

ROE

-4.6%

Above 22% of the 39 companies in its industry, and 24% of all.

ROA

-2.0%

Above 21% of the 41 companies in its industry, and 26% of all.

Revenue growth

-0.9%

Above 34% of the 40 companies in its industry, and 26% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CIK
1100682
Exchange
NYSE
Industry (SIC)
8731 · Services-Commercial Physical & Biological Research
Fiscal year ends
December 27
Latest annual report
December 27, 2025
Reporting currency
USD
Shares
49.23M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Charles River Laboratories International's filings show?

These are Charles River Laboratories International's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about CRL

Didn't find what you were looking for?

Ask us
What is CRL's market cap?

Charles River Laboratories International, Inc.'s market cap is $16.6B, at a price of $337.97 on November 13, 2026 and 49.23M shares.

How much revenue does CRL have?

Charles River Laboratories International had revenue of $4.0B over the last 12 months. Over the last 5 years it changed by +6.6% a year on average.

Does CRL pay a dividend?

No. Charles River Laboratories International paid no regular dividend over the last 12 months.

Where do the figures come from?

From Charles River Laboratories International, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.